News
- Author:
- Bruce Jancin
Publish date: January 20, 2019
CHICAGO – Japanese EWTOPIA 75 study provides first RCT evidence of benefit for LDL-lowering in seniors.
News
- Author:
- Bruce Jancin
Publish date: January 17, 2019
CHICAGO – Overweight and obese VA stroke patients have lower 30-day and 1-year all-cause mortality after an in-ho...
News
- Author:
- Bruce Jancin
Publish date: January 17, 2019
CHICAGO – Aggressive oversizing of self-expanding stent grafts is the strongest modifiable risk factor.
News
- Author:
- Bruce Jancin
Publish date: January 15, 2019
CHICAGO – Bempedoic acid will also be tested in combination with ezetimibe in a single pill.
News
- Author:
- Bruce Jancin
Publish date: January 15, 2019
BARCELONA - "There are patients in our clinics all of us - neurologists and psychiatrists - are missing."
News
- Author:
- Bruce Jancin
Publish date: January 14, 2019
CHICAGO – A reappraisal of the landmark ATTRACT trial shows benefit in iliofemoral intervention for acute deep ve...
News
- Author:
- Bruce Jancin
Publish date: January 13, 2019
PARIS – Pooled analysis of phase 3 trials spotlights one clinical setting where brodalumab is particularly advantageous.
News
- Author:
- Bruce Jancin
Publish date: January 11, 2019
PARIS – Adult atopic dermatitis patients have higher prevalence of psoriasis, alopecia areata, vitiligo, and other dermatologic disorders.
News
- Author:
- Bruce Jancin
Publish date: January 8, 2019
PARIS – Birth complications are uncommon for women with atopic dermatitis in pregnancy.
News
- Author:
- Bruce Jancin
Publish date: January 8, 2019
PARIS – There is no approved medication in the United States or Europe for the often intense itching associated with chronic kidney disease.
News
- Author:
- Bruce Jancin
Publish date: January 3, 2019
PARIS – More than 90% of PASI 75 responders to tildrakizumab at 6 months maintained at least a PASI 75 response at 148 weeks.
News
- Author:
- Bruce Jancin
Publish date: January 3, 2019
BARCELONA – The evolutionary treatment targets reconsolidation of fear memories.
News
- Author:
- Bruce Jancin
Publish date: January 3, 2019
PARIS – Results of the first-ever randomized trial of biologic dose reduction in well-controlled psoriasis patients are reported.
News
- Author:
- Bruce Jancin
Publish date: January 2, 2019
BARCELONA – Novel program is designed for treatment-resistant combat PTSD but might have broader applications.
News
- Author:
- Bruce Jancin
Publish date: December 27, 2018
CHICAGO – A phase 2b trial of a novel antihypertensive drug checks off efficacy and safety boxes.
